Aligning Disruptive Innovation, Digital Health, Commercial and Customer Strategy
Following the success of Digital Pharma East; the worlds largest Digital Marketing event for life sciences with over 950 attendees, The Digital pharma Series is delighted to launch it’s inaugural event in Japan.
Following sustained success in Europe (9 years) and China (5 years), the stage is set to deliver a world class event for Japanese pharmaceutical and medical device executives to learn how to embed a digital ecosystem that is tailored for execution specifically in the Japanese business model.
Join your peers at the event to engage and discuss these key themes:
How will digital disruption transform the pharma business model?
Unlike other industries, the “Uber” of the pharma industry has yet to emerge, and the market remains ripe for digital disruption. Pharma companies are exploring how to transform through change management and new business models to better engage their customers, and streamline their operations, and stay competitive.
How can pharma generate value from digital medicine solutions?
As pharma companies shift from implementing traditional products to connected solutions, companies are challenged to define and realize value from this new business model (e.g. revenue stream) that intelligent, digital medicine solutions require.
How can pharma engage with disruptive technologies?
AI, AR, and cognitive computing are now a reality and are being used by doctors and physicians in predictive diagnostics. If we start to advance toward diagnostics from AI on a regular basis and certain decision-making processes out of the doctors’ hands, what are the implications for pharma marketing? How will brands and marketing teams adapt to this new world?
How can we demonstrate the value of digital for pharma products?
Pharma companies are increasingly exploring the role digital can play in demonstrating value through data, analytics, and real-world evidence.
How will pharma adapt to successfully engage HCPs?
As HCPs evolve in their engagement with patients and how they manage their practice, pharma companies will have to transform their HCP-engagement approach.